Search

Issue
Title
Authors
Klinicheskiy sluchay uspeshnogo lecheniya erilibulinom metastaticheskogo raka molochnoy zhelezy
Limareva S.V., Laytsan K.Y., Stroyakovskiy D.L., Demidova I.A., Gorbunova V.A.
Algorithm for diagnostics and systemic therapy of metastatic hormone-sensitive HER2-negative breast cancer
Dashyan G.A., Olchonova A.A., Dzhelyalov E.S., Akhmedov R.M., Sereda O.A., Vats A.B., Zhurov A.S., Shaikhelislamova L.F., Pushkaruk G.A., Belousov A.M.
The role of alpelisib in the treatment of PIK3CA - a mutated breast cancer
Semiglazov V.F., Krivorotko P.V., Komyakhov A.V., Semiglazova T.Y., Gigolaeva L.P., Tabagua T.T., Kazantseva M.D., Tergoeva A.P., Ulrikh D.G., Chervyak M.V., Klimenko V.V., Amirov N.S., Zhiltsova E.K., Semiglazov V.V.
Assessing the risk of recurrence of luminal HER2-negative breast cancer and the possibility of intensifying adjuvant hormonal therapy to reduce the risk of progression
Gordeeva O.O.
Experience of the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative breast cancer
Glazkova E.V., Frolova M.A., Menshikov S.F., Stenina M.B.
Abemacyclib is a unique representative of the class of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer
Grechukhina K.S., Vorontsova K.A., Kuko T.M., Prosvirnov A.A., Ganshina I.P., Lubennikova E.V., Kolyadina I.V., Zhukova L.G.
The role of cyclin-dependent kinase inhibitors in adjuvant therapy of breast cancer
Semiglazov V.F., Krivorotko P.V., Bekkeldiyeva N.B., Komyakhov A.V., Emelyanov A.S., Gorina A.O.
Eribulin – novyy mikrotrubochkovyy ingibitor dlya lecheniya metastaticheskogo raka molochnoy zhelezy
Stenina M.B.
Neoadjuvant and postneoadjuvant treatment for triple negative breast cancer
Semiglazov V.F., Dzhelyalova M.A., Tseluyko A.I., Pesotsky R.S., Bessonov A.A., Semiglazova T.Y.
Structural and functional changes in the thyroid gland in the early and late periods after radiation therapy
Amergulov I.I., Pavlova M.G., Sych Y.P., Zhuravleva Y.R., Dolov M.M., Berdyklychev M.T., Dobrokhotova V.Z., Sannikova E.O., Trofimova O.P., Orlova M.V., Kuznetsova D.A., Bychkova N.M., Zaitseva N.A., Kandakova E.Y., Sotnikov V.M., Ryzhkova E.G., Fadeev V.V.
Perspektivy primeneniya kapsul vinorelbina v sovremennoy onkologii
Gutorov S.L., Stepanchenko M.V., Lichinitser M.R.
Non-small lung cancer. Expanding therapeutic opportunities: pembrolizumab in a number of malignant tumors
Gutorov S.L., Borisova E.I., Abramov M.E., Lud A.N., Arutyunyan E.A.
Osobennosti klinicheskogo techeniya invazivnogo dol'kovogo raka molochnoy zhelezy
Borisova E.I., Vyshinskaya G.V., Gutorov S.L., Stepanchenko M.V.
Novye vozmozhnosti ispol'zovaniya targetnoy terapii v lechenii nekotorykh solidnykh opukholey (po materialam ESMO-2014)
Dobrova N.V.
Evaluation of long-term results of treatment of patients with residual tumors (including those with minimal forms of ypT1abN0), with pathomorphological complete response (pCR) after neoadjuvant systemic therapy, with primary minimal breast cancer (pT1abN0M0)
Pesotsky R.S., Semiglazov V.F., Krivorotko P.V., Tabagua T.T., Zernov K.Y., Emelyanov A.S., Semiglazova T.Y., Amirov N., Mortada V.V., Ulrikh D.G., Levchenko V.E., Rychagov K.Y., Zirov K.Y., Evseev V.N.
A new approach to the overcoming resistance to hormone therapy of breast cancer
Semiglazova T.Y., Semiglazov V.V., Filatova L.V., Krivorot'ko P.V., Klimenko V.V., Gershanovich M.L., Semiglazov V.F.
IMAGING OF INDIVIDUAL LYMPH OUTFLOW TRACTS FOR DETERMINATION OF TOPOGRAPHY OF RADIATION FIELD IN BREAST CANCER PATIENTS
Kanaev S.V., Novikov S.N., Krivorot'ko P.V., Semiglazov V.F., Zhukova L.A., Zotova O.V., Kanaev S., Novikov S.V.
NEOADJUVANT THERAPY OF THE BREAST CANCER WITH HIGH EXPRESSION OF HER-2
Semiglazov V.F., Manikhas A.G., Bozhok A.A., Dashjan G.A., Vasilev A.G., Petrovsky S.G., Matsko D.Y., Semiglazov V.V., Paltuev R.M., Ivanov V.G., Zernov K.Y., Donskikh R.V., Bessonov A.A., Shamina Y.A., Semiglazov V.F., Manikhas A.G., Bozhok A.A., Vasil'ev A.G., Petrovskiy S.G., Matsko D.E., Semiglazov V.V., Dashyan G.A., Paltuev R.M., Ivanov V.G., Zernov K.Y., Donskikh R.V., Bessonov A.A., Shamina E.A.
The influence of CYP3A5, CYP2D6, CYP2C19 and ABCB1 gene polymorphisms on the levels of minimum steady-state concentration of doxorubicin and troponin I in patients with breast cancer: an observational cross-sectional study
Bagdasaryan A.A., Shikh E.V., Drozdov V.N.
Trastuzumab deruxtecan in the treatment of breast cancer
Semiglazov V.F., Krivorotko P.V., Bekkeldieva N.B., Gorina A.O., Komyakhov A.V., Paltuev R.M., Tabagua T.T., Ereshenko S.S.
Treatment of locally advanced (T2-3N0-1M0) and early (T1-2N0M0) HER2-positive breast cancer (clinical experience)
Semiglazov V.F., Komyakhov A.V., Yerechshenko S.S., Tabagua T.T., Gigolaeva L.P., Tseluyko A.I., Tergoeva A.P., Kazantseva M.D., Amirov N.S., Mortada V.V., Pesotsky R.S., Enaldieva D.A., Shaihelislamova L.F., Nikolaev K.S., Zhiltsova E.K., Krivorotko P.V.
Ways to improve endocrine therapy in postmenopausal women with ER+/ HER2- breast cancer
Dzhelyalova M.A., Semiglazov V.F.
Predictive and prognostic significance of stemness gene amplifications in the breast tumor in patients who received neoadjuvant chemotherapy
Kazantseva P.V., Slonimskaya E.M., Tsyganov M.M., Ibragimova M.K., Doroshenko A.V., Tarabanovskaya N.A., Litviakov N.V.
De-escalation and escalation of treatment of patients with HER2-positive breast cancer
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Komyakhov A.V., Semiglazova T.Y., Paltoev R.M., Donskikh R.V., Tseluyko A.I., Artemyeva A.S., Bashlyk V.O., Miryusupova G.F., Dashyan G.A.
BONDRONAT - OPYT PRIMENENIYa U BOL'NYKh S KOSTNYMI METASTAZAMI RAKA MOLOChNOY ZhELEZY
Semenov N.N.
Effektivnost' i bezopasnost' preparata Ekstimiya®, novogo pegilirovannogo filgrastima: rezul'taty otkrytogo sravnitel'nogo klinicheskogo issledovaniya II fazy patsientov s rakom molochnoy zhelezy, poluchayushchikh mielosupressivnuyu khimioterapiyu
Sheveleva L.P., Khorinko A.V., Burdaeva O.N., Nechaeva M.N., Matrosova M.P., Kovalenko N.V., Ivanov R.A., Chernovskaya T.V., Salafet O.V.
Chemotherapy of anthracy-clineand taxan-resistant breast cancer
Kovalenko E.I., Satirova E.F., Artamonova E.V., Manzyuk L.V.
CLINICAL EXPERIENCE OF USE OF BEVACIZUMAB (AVASTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH UNIDENTIFIED HER2/NEW AND ER PR-RECEPTOR STATUS
Konstantinova M.M., Shikina V.E., Makshantsev A.Y., Konstantinova M.M., Shikina V.Y., Makshantsev A.Y.
Primary resistance to anti-HER2 therapy: mechanisms of development and ways to overcome
Dashyan G.A., Dzhelialov E.S., Konstantinova V.V., Gronskaya Y.A., Murskikh A.D., Akhmedov R.M., Tyusenko A.E., Olchonova A.A., Dyakonenko Z.V., Sereda O.A., Belousov A.M.
Clinical significance of genetic polymorphism of tamoxifen metabolic enzymes and transporters in breast cancer: results of a population-based cohort study
Golubenko E.O., Savelyeva M.I., Sozaeva Z.A., Poddubnaya I.V., Korennaya V.V.
Dual HER2 blockade with pertuzumab+trastuzumab on the eve of a new era in the treatment of HER2-positive breast cancer
Zhukova L.G., Artamonova E.V., Ganshina I.P., Kolyadina I.V., Vorontsova K.A., Sekhina O.V., Grechukhina K.S.
Abemacyclib - new options for the treatment of hormone-positive metastatic breast cancer with CDK4/6 inhibitors
Semiglazova T.Y., Volynshchikova O.A., Semiglazov V.V., Klimenko V.V., Brish N.A., Alekseeva Y.V., Klyuge V.A., Krutov A.A., Paltuev R.M., Kasparov B.S., Krivorotko P.V., Semiglazov V.F.
Ways to improve efficiency of endocrino-therapy of breast cancer: new targeted cells, new therapeutic opportunities
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Dashyan G.A., Komyakhov A.V., Paltuev R.M., Appolonova V.S., Donskikh R.V., Tseluyko A.I., Semiglazova T.Y., Zhiltsova E.K., Krivorotko P.V.
Ixempra - new possibilities of cytostatic therapy of breast cancer
Lubennikova E.V., Zhukova L.G., Arutyunyan E.A.
EFFECT OF SPECIAL TREATMENT ON THE DEVELOPMENT OF OSTEOPOROSIS IN PATIENTS WITH BREAST CANCER IN PREMENOPAUSAL PERIOD
Tretyakova N.Y.
ROL' LIPOSAKTsII V LEChENII POSTMASTEKTOMIChESKOY LIMFEDEMY
Zabelin M.V., Sidorov D.B., Safonov A.S.
PRIMENENIE BISFOSFONATOV DLYa PROFILAKTIKI RAZVITIYa KOSTNYKh METASTAZOV U BOL'NYKh RAKOM MOLOChNOY ZhELEZY
Semenov N.N.
Opyt primeneniya trastuzumaba v respublike Bashkortostan
Sakaeva D.D., Kunafina R.I., Popova E.V.
TARGETED THERAPY OF BREAST CANCER (NEW DIRECTIONS)
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Manikhas A.G., Bessonov A.A., Ermachenkova A.M., Shchedrin D.E., Tabagua T.T., Grechukhina I.A., Krivorot'ko P.V., Donskikh R.V., Semiglazova T.Y., Kolar'kova V.V., Semiglazo V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Manikhas A.G., Bessonov A.A., Yermachenkova A.M., Schedrin D.Y., Tabagua T.T., Grechukhina I.A., Krivorotko P.V., Donskih R.V., Semiglazova T.Y., Kolarkova V.V.
Analysis of pharmacotherapy in patients with HR+HER2- metastatic breast cancer with PIK3CA mutations in real clinical practice
Fateeva A.V., Eliseeva E.V., Apanasevich V.I., Zaemskaya A.A.
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
Orlova R.V., Gluzman M.I., Vakhitova A.A.
Ixabepilone in the treatment of breast cancer
Semiglazov V.F., Krivorotko P.V., Semiglazova T.Y., Komyakhov A.V., Tabagua T.T., Kazantseva M.D., Zhiltsova E.K., Ulrikh D.G., Chervyak M.V., Tergoeva A.P., Klimenko V.V., Semiglazov V.V.
Olaparib -modern approach to the treatment of BRCA-associated HER2-negative metastatic breast cancer. Clinical experience
Lubennikova E.V., Zhukova L.G., Gordeeva O.O., Drobot N.T., Kuznetsov A.V., Ganshina I.P.
Treatment of residual breast cancer
Ereschenko S.S., Semiglazov V.F., Krivorotko P.V., Dashyan G.A., Smirnova V.O., Komyakhov A.V., Gigolaeva L.P., Zhiltsova E.K.
ANALYSIS OF INFLUENCE ON THE BUDGET OF THE RUSSIAN FEDERATION OF THE USE OF ORAL VINORELBINE FOR THE TREATMENT OF METASTATIC BREAST CANCER
Shabalkin P.I.
Novyy sposob radikal'noy rezektsii pri rake molochnoy zhelezy nizhnikh lokalizatsiy
Parandey I.N., Orlov O.A.
EVEROLIMUS (AFINITOR): NOVYE VOZMOZhNOSTI TERAPII ZLOKAChESTVENNYKh OPUKhOLEY
Gorbunova V.A.
NOVYE VOZMOZhNOSTI TERAPII BOL'NYKh METASTATIChESKIM RAKOM MOLOChNOY ZhELEZY, POLUChAVShIKh RANEE ANTRATsIKLINI TAKSAN-SODERZhAShchUYu KhIMIOTERAPIYu: OBZOR LITERATURY I KLINIChESKIY SLUChAY
Zhukova L.G.
Effektivnost' i bezopasnost' ezhenedel'nogo vvedeniya paklitaksela bol'nym metastaticheskim rakom molochnoy zhelezy: rezul'taty prospektivnogo mnogotsentrovogo klinicheskogo issledovaniya
Stroyakovskiy D.L., Makhson A.N., Bolotina L.V., Gorbunova V.A., Koroleva L.A., Bagrova S.G., Borisova T.A., Kornietskaya A.L., Ivanov R.A., Nikitin K.D.
INDIVIDUALIZATION OF ADJUVANT THERAPY OF BREAST CANCER
Semiglazov V.F., Semiglazov V.V., Paltuev R.M., Dashyan G.A., Manikhas A.G., Pen'kov K.D., Semiglazova T.Y., Tabagua T.T., Vasil'ev A.G., Kolar'kova V.V., Krivorot'ko P.V., Nikitina I.V., Semiglazov V.F., Semiglazov V.V., Paltuyev R.M., Dashyan G.A., Manihas A.G., Penkov K.D., Semiglazova T.Y., Tabagua T.T., Vasilyev A.G., Korolkova V.V., Krivorotko P.V., Nikitina I.V.
GSTT1 and GSTM1 deletion polymorphism as a predictor of response to hormonal therapy for breast cancer
Gulian I.S., Bystritskaya E.P., Otstavnykh N.Y., Khudchenko E.V., Eliseeva E.V., Apanasevich V.I., Isaeva M.P.
Sentinel lymph node scintigraphy in breast cancer. Own experience
Afanasyeva N.G., Vazhenin A.V., Trofimchuk L.Y., Chvanova K.V.
A clinical case of using ribociclib with an aromatase inhibitor in metastatic hormone-receptor-positive HER2-negative breast cancer with a rare location of metastasis
Fateeva A.V., Zyuzyukina A.V., Zukov R.A.
EXPERIENCE OF PERSONALIZED APPOINTMENT OF NEOADJUVANT CHEMOTHERAPY FOR PATIENT WITH BREAST CANCER: A PROSPECTIVE STUDY
Slonimskaya E.M., Kazantseva P.V., Litviakov N.V., Tsyganov M.M., Ibragimova M.K., Doroshenko A.V., Vernadsky R.U., Vostrikova M.A., Lushnikova N.A.
PLACE OF LAPATINIB IN THE THERAPY OF HER2-POSITIVE BREAST CANCER
Zhukova L.G., Ganshina I.P., Zaitsev V.G., Stepanchenko M.V.
KOMPLEKSNAYa TERAPIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Semiglazov V.V., Nikolaev K.S., Dashyan G.A., Paltuev R.M.
NOVYE PERSPEKTIVNYE PREPARATY DLYa LEChENIYa HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Gorbunova V.A.
ROL' IMMUNOKON\"YuGATOV V TARGETNOY TERAPII ZLOKAChESTVENNYKh OPUKhOLEY
Semiglazov V.F., Dashyan G.A., Semiglazova T.Y., Paltuev R.M., Zernov K.Y., Pen'kov K.D., Grechukhina I.A., Semiglazov V.V.
Effektivnost' nizkikh doz gemtsitabina v kombinatsii s tsisplatinom v lechenii disseminirovannogo raka molochnoy zhelezy s progressirovaniem posle primeneniya antratsiklinov, taksanov i kapetsitabina
Semiglazova T.Y., Gershanovich M.L., Latipova D.K., Filatova L.V., Chubenko V.A., Semiglazov V.V., Matsko D.E., Klimenko V.V.
RESORBA IN THE TREATMENT OF BONE METASTASIS OF BREAST CANCER
Vladimirova L.Y., Abramova N.A., E Storozhakova A., Paly A.L., Vladimirova L.Y., Abramova N.A., Storozhakova A.E., Paliy A.L.
Adherence to adjuvant hormonal therapy for luminal HER2-negative breast cancer: results of a patient survey
Gordeeva O.O., Bokova S.E.
Reconstructive plastic surgery of the breast using autogenous tissue. Historical aspects
Khakimova S.G., Zikiryakhodzhaev A.D., Kaprin A.D., Khakimova G.G., Onofriychuk I.M., Rasskazova E.A., Sukhotko A.S., Vlasova M.Y., Bosieva A.R., Tokaev V.K.
Treatment of HER2-positive early (minimal) breast cancer
Pesotsky R.S., Semiglazov V.F., Tseluyko A.I., Sokolova M.D., Mortada V.V., Tabagua T.T., Krivorotko P.V.
New possibilities of neoadjuvant treatment of ER+ HER2- breast cancer in premenopausal patients
Orlova R.V., Vakhitova A.A., Gluzman M.I.
New results of combination endocrinotherapy with ribocyclib
Kolyadina I.V.
CYCLIN-DEPENDENT KINASE INHIBITORS - NEW THERAPEUTIC OPTION FOR PATIENTS WITH HORMONE-DEPENDENT HER2-NEGATIVE BREAST CANCER: CLINICAL EXPERIENCE
Sakaev D.D., Iskhakova A.I., Kunafina R.I.
TAXANES IN THE TREATMENT OF BREAST CANCER
Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Paltuev R.M., Semiglazova T.Y., Donskikh R.V., Nikolaev K.S., Komyakhov A.V., Zernov K.Y., Krivorotko P.V.
NEOADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Krivorotko P.V., Nikolaev K.S., Semiglazova T.Y., Komyakhov A.V., Bessonov A.A., Donskikh R.V., Paltuev R.M., Zernov K.Y.
Eribulin v lechenii metastaticheskogo raka molochnoy zhelezy s troynym negativnym fenotipom
Zhukova L.G., Okruzhnova M.A., Chasovnikova E.O.
METODOLOGIChESKIE ASPEKTY MORFOLOGIChESKOY DIAGNOSTIKI I OTsENKI LEChEBNOGO PATOMORFOZA TROYNOGO NEGATIVNOGO RAKA MOLOChNOY ZhELEZY
Andreeva Y.Y., Zavalishina L.E., Danilova N.V., Ilatovskaya M.E., Frank G.A.
ChETYRE ASPEKTA AD\"YuVANTNOY TARGETNOY TERAPII HER2-POZITIVNOGO RAKA MOLOChNOY ZhELEZY
Semiglazov V.F., Semiglazov V.V.
XELODA IN BREAST CANCER: THE EXPERIENCE OF LONG-TERM USE
Vladimirova L.Y., Popova I.L., Vladimirova L.Y., Popova I.L.
DRUG ZOMETA IN ADDITION TO THE CHEMOTHERAPY SIGNIFICANTLY INCREASES OVERALL SURVIVAL IN PREVIOUSLY UNTREATED PATIENTS WITH MULTIPLE MYELOMA
Zhukov N.V., Zhukov N.V.
Delay of initiation of adjuvant chemotherapy in patients with early breast cancer: causes and consequences
Dashyan G.A., Konstantinova V.V., Dzhelialov E.S., Akhmedov R.M., Semiletova Y.V., Zhurov A.S., Tyusenko A.E., Olchonova A.A., Pavlikova I.A., Belousov A.M.
Predictive and prognostic role of tumor-infiltrating lymphocytes (TILs) in early triple-negative breast cancer
Abdulaeva S.R., Semiglazova T.Y., Artemyeva A.S., Kudaibergenova A.G., Sharashenidze S.M., Tseluyko A.I., Paltuev R.M., Semiglazov V.V., Krivorotko P.V., Semiglazov V.F.
Search for new prognostic and predictive markers of sensitivity to endocrine therapy, chemotherapy and immunotherapy of breast cancer
Semiglazov V.F., Pesotsky R.S., Tseluiko A.I., Dzhelyalova M.A., Apollonova V.S., Semiglazov V.V.
GONADOTROPIN-RELEASING HORMONE AGONISTS-INDUCED OVARIAN SUPPRESSION IN EARLY BREAST CANCER
Semiglazova T.Y., Berlev I.V., Ulrikh E.A., Semiglazov V.V., Protasova A.E., Brish N.A., Korobeynikova E.A., Alekseeva Y.V., Filatova L.V., Semenova A.I., Latipova D.K., Teletaeva G.M., Tkachenko E.V., Klimenko V.V., Dashyan G.A., Protsenko S.A., Paltuev R.M., Urmancheeva A.F., Krivorotko P.V., Semiglazov V.F.
RESOLUTION SUMMARIZING THE RESULTS OF THE EXPERT COUNCIL "MODERN APPROACHES TO THE TREATMENT OF HER2-NEGATIVE METASTATIC BREAST CANCER. PROSPECTS FOR THE USE OF ERIBULIN AS A PART OF COMBINATION THERAPY FOR BREAST CANCER"
Artamonova E.V., Bolotina L.V., Gligorov Z., Zhukov N.V., Zhukova L.G., Imyanitov E.N., Karabina E.V., Kovalenko E.I., Lichinitser M.R., Manzyuk L.V., Semiglazov V.F., Semiglazova T.Y., Stroyakovsky D.L.
Redkiy sluchay otdalennogo metastazirovaniya raka molochnoy zhelezy v okoloushnuyu slyunnuyu zhelezu
Krasikova Y.P., Klochikhin M.A., Klochikhin A.L.
Rak molochnoy zhelezy i beremennost'
Dashyan G.A., Semiglazov V.F., Topuzov E.E., Ivanov V.G., Vorotnikov V.V., Lalak I.A., Bryantseva Z.V., Usungvan M.V., Tseluyko A.I.
Adjuvant hormonal therapy in perimenopausal women with ER-positive breast cancer
Semiglazov V.F., Semiglazov V.V.
TARGETED THERAPY AFTER PROGRESSION OF HER-2-POSITIVE BREAST CANCER
Tat'yana Y.S., Semiglazov V.V., Larisa V.F., Chubenko V.A., Nikita V.B., Fedor V.M., Latipova D.K., Mikhail L.G., Semiglazova T.Y., Semiglazov V.V., Filatova L.V., Chubenko V.A., Brejnev N.V., Moiseenko F.V., Latipova D., Gershanovich M.L.
TARGET THERAPY HER2-POSITIVE BREAST CANCER WITH BRAIN METASTASES: NEW PROSPECTS FOR TREATMENT
Yu Semiglazova T., Filatova L.V., Kh Latipova D., Gershanovich M.L., Semiglazova T.Y., Filatova L.V., Khamidovna L.D., Gershanovich M.L.
Frequency and spectrum of PIK3CA mutations in hormone-dependent HER2-negative breast cancer: a single-center experience
Romashkina N.V., Klishina M.V., Karabina E.V.
Analysis of the effectiveness of various neoadjuvant chemotherapy regimens in patients with T1-3N1-3M0 I–IIIC stage locally advanced breast cancer
Pesotsky R.S., Semiglazov V.F., Krivorotko P.V., Tabagua T.T., Zernov K.Y., Emelyanov A.S., Yerechshenko S.S., Amirov N., Mortada V.V., Ulrikh D.G., Levchenko V.E., Rychagov K.Y., Zirov K.Y., Evseev V.N.
Clinical immunology of breast cancer
Tseluiko A.I., Semiglazov V.F., Kudaibergenova A.G., Artemyeva A.S., Paltuev R.M., Donskikh R.V., Pesotsky R.S., Krivorotko P.V.
Oral chemotherapy with vinorelbine for advanced breast cancer: its role in clinical practice
Sakaeva D.D., Nasretdinov A.F.
New possibilities of the treatment of breast cancer: microtubule inhibitors
Semiglazov V.F., Dashyan G.A., Krivorotko P.V., Paltuev R.M., Donskikh R.V., Semiglazova T.Y., Zernov K.Y., Gigolaeva L.P., Apollonova V.S.
FIRST-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE METASTATIC BREAST CANCER. TIME OF CHANGE AFTER A LONG-TERM CALM PERIOD
Zhukova L.G., Manikhas A.G.
15-letniy opyt ispol'zovaniya Gertseptina pri HER2-pozitivnom rake molochnoy zhelezy
Mukhametshina G.Z., Lichinitser M.R., Lubennikova E.V.
Znachenie molekulyarnykh markerov pri vybore neoad\"yuvantnoy khimioterapii mestno-rasprostranennogo raka molochnoy zhelezy
Semiglazova T.Y., Semiglazov V.V., Filatova L.V., Krivorot'ko P.V., Klimenko V.V., Ivanov V.G., Novikov S.M., Gershanovich M.L., Imyanitov E.N., Semiglazov V.F.
Adjuvant therapy with trastuzumab for early-stage breast cancer: 12 or 24 months (based on ESMO data, Vienna, october, 2012)
Zhukova L.G., Lichinitser M.R.
EVALUATION OF THE EFFECTIVENESS OF CHEMOTHERAPY OF BREAST CANCER WITH LUNG METASTASES
Andreyashkina I.I., Plokhov V.N., Andreyashkina I.I., Plokhov V.N.
ADJUVANT ANTI-HER2 THERAPY FOR BREAST CANCER
Semiglazov V.F., Semiglazov V.V., Ivanov V.G., Bessonov A.A., Shchedrin D.Y., Zhiltsova Y.K., Dashyan G.A., Paltuev R.M., Semiglazova T.Y., Penkov K.D., Vasilyev A.G., Semiglazov V.F., Semiglazov V.V., Ivanov V.G., Bessonov A.A., Shchedrin D.E., Zhil'tsova E.K., Dashyan G.A., Paltuev R.M., Semiglazova T.Y., Pen'kov K.D., Vasil'ev A.G.
Will our clinical practice change with the availability of new diagnostic methods, drug therapy and assessment of its effectiveness? Clinical case: hormone receptor-positive, HER2-negative metastatic breast cancer
Konstantinova M.M., Kuzina L.I.
Endocrine resistance in breast cancer treatment
Dzhelyalova M.A., Semiglazov V.F.
Trastuzumab emtanzin in the treatment of HER2-positive metastatic breast cancer in patients with visceral crisis
Vladimirova L.Y., Popova I.L., Abramova N.A., Storozhakova A.E., Tikhanovskaya N.M., Novoselova K.A., Lyanova A.A., Ryadinskaya L.A., Yezhova M.O., Teplyakov M.A.
Palbociclib - new possibilities of therapy of hormon-positive HER2-negative breast cancer
Zhukova L.G., Chichikov E.I., Gordeeva O.O., Filonenko D.A.
Kadsila (trastuzumab emtanzin, T-DM1): pervyy kon\"yugat antitela i khimiopreparata v lechenii HER2-polozhitel'nogo raka molochnoy zhelezy
Borisova E.I., Gutorov S.L., Lichinitser M.R.
LAPATINIB PRI RAKE MOLOChNOY ZhELEZY
Fray I.V., Perevodchikova N.I.
1 - 100 of 101 Items 1 2 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"